Orbimed Advisors LLC Trims Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Orbimed Advisors LLC reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 58.8% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 119,000 shares of the biopharmaceutical company’s stock after selling 169,800 shares during the quarter. Orbimed Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $39,374,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. MV Capital Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $25,000. HM Payson & Co. bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $27,000. Golden State Wealth Management LLC increased its position in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Finally, Manchester Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $271.77 on Monday. The company has a market capitalization of $36.28 billion, a PE ratio of 74.25 and a beta of 0.27. Alnylam Pharmaceuticals, Inc. has a one year low of $262.21 and a one year high of $495.55. The company’s 50 day moving average price is $292.22 and its two-hundred day moving average price is $316.06. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the company earned ($0.44) EPS. The firm’s revenue was up 96.4% on a year-over-year basis. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Truist Financial lowered their price objective on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, Bank of America reduced their target price on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $452.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.